Literature DB >> 29792066

Capabilities of Next-Generation Patch Pump: Improved Precision, Instant Occlusion Detection, and Dual-Hormone Therapy.

Forrest W Payne1, Bradley Ledden1, Greg Lamps1.   

Abstract

Insulin pumps allow patients to attain better blood glucose control with more lifestyle flexibility. Their size and cost, however, limit their usefulness. Current CSII pumps are bulky, intrusive, and expensive. SFC Fluidics is addressing these problems by developing a new type of wearable patch pump based on the patented electro-chemiosmotic (ECO) microfluidic pumping technology. This nonmechanical pumping technology allows accurate and precise delivery of very small amounts of insulin and/or other drugs, including concentrated insulin. The pump engine is small and can be made inexpensively from injection molded parts, allowing its use in a disposable or semidisposable pod format. In addition, a single ECO pump engine can be used to deliver two drugs through independent pathways. Other features of SFC Fluidics' pod include latching safety valves that prevent accidental overdosing of insulin due to pressure changes and an instantaneous occlusion sensor that can immediately detect delivery failure at the first missed dose. These features allow for the development of a series of patch pumps that will offer users the benefit of CSII therapy in a more discreet and reliable patch pump form.

Entities:  

Keywords:  artificial pancreas; automated insulin delivery; concentrated insulin; dual-hormone therapy; insulin patch pump; occlusion detection

Mesh:

Substances:

Year:  2018        PMID: 29792066      PMCID: PMC6313296          DOI: 10.1177/1932296818776028

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  17 in total

1.  A Comparison of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Insulin Injection in Children with Type I Diabetes in Kuwait: Glycemic Control, Insulin Requirement, and BMI.

Authors:  Mohammad Mousa; Maria Al-Mahdi; Hala Al-Sanaa; Hessa Al-Kandari
Journal:  Oman Med J       Date:  2015-09

2.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.

Authors:  Ahmad Haidar; Laurent Legault; Virginie Messier; Tina Maria Mitre; Catherine Leroux; Rémi Rabasa-Lhoret
Journal:  Lancet Diabetes Endocrinol       Date:  2014-11-27       Impact factor: 32.069

3.  Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.

Authors:  Ahmad Haidar; Laurent Legault; Maryse Dallaire; Ammar Alkhateeb; Adèle Coriati; Virginie Messier; Peiyao Cheng; Maude Millette; Benoit Boulet; Rémi Rabasa-Lhoret
Journal:  CMAJ       Date:  2013-01-28       Impact factor: 8.262

Review 4.  Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.

Authors:  Marie L Misso; Kristine J Egberts; Matthew Page; Denise O'Connor; Jonathan Shaw
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion.

Authors:  Lutz Heinemann; Lars Krinelke
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

6.  Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.

Authors:  P G Jacobs; J El Youssef; R Reddy; N Resalat; D Branigan; J Condon; N Preiser; K Ramsey; M Jones; C Edwards; K Kuehl; J Leitschuh; U Rajhbeharrysingh; J R Castle
Journal:  Diabetes Obes Metab       Date:  2016-08-15       Impact factor: 6.577

7.  Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies.

Authors:  Peter G Jacobs; Joseph El Youssef; Jessica Castle; Parkash Bakhtiani; Deborah Branigan; Matthew Breen; David Bauer; Nicholas Preiser; Gerald Leonard; Tara Stonex; W Kenneth Ward
Journal:  IEEE Trans Biomed Eng       Date:  2014-05-13       Impact factor: 4.538

8.  Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas.

Authors:  Steven J Russell; Firas H El-Khatib; David M Nathan; Kendra L Magyar; John Jiang; Edward R Damiano
Journal:  Diabetes Care       Date:  2012-08-24       Impact factor: 19.112

9.  Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies.

Authors:  Michael Gibney; Zhenyi Xue; Monica Swinney; Damian Bialonczyk; Laurence Hirsch
Journal:  Diabetes Technol Ther       Date:  2015-12-24       Impact factor: 6.118

10.  Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home.

Authors:  H Blauw; A C van Bon; R Koops; J H DeVries
Journal:  Diabetes Obes Metab       Date:  2016-04-25       Impact factor: 6.577

View more
  4 in total

1.  Patch Pumps: Are They All the Same?

Authors:  Lutz Heinemann; Delia Waldenmaier; Bernd Kulzer; Ralph Ziegler; Barry Ginsberg; Guido Freckmann
Journal:  J Diabetes Sci Technol       Date:  2018-08-22

2.  Insulin Pumping Patches: Emerging Insulin Delivery Systems.

Authors:  Bithika Thompson; Curtiss B Cook
Journal:  J Diabetes Sci Technol       Date:  2018-11-22

Review 3.  Patch Pumps for Insulin.

Authors:  Barry H Ginsberg
Journal:  J Diabetes Sci Technol       Date:  2018-08-02

4.  MiniMed 670G hybrid closed loop artificial pancreas system for the treatment of type 1 diabetes mellitus: overview of its safety and efficacy.

Authors:  Aria Saunders; Laurel H Messer; Gregory P Forlenza
Journal:  Expert Rev Med Devices       Date:  2019-09-30       Impact factor: 3.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.